OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated KEYNOTE-695 Study Data
SITC KOL webinar on November 12 at 7 a.m. ET
Pennington, New Jersey and SAN DIEGO, November 2, 2021 / PRNewswire / – OncoSec Medical Incorporated (NASDAQ: ONCS) to host conference call and webcast for investors and analysts on Friday 12 November To 7:00 a.m.ET featuring key opinion leaders (KOLs) Matteo carlino, MD, Westmead and Blacktown Hospitals, Adil daud, MD, from University of California San Francisco, Pablo Fernandez Peñas MD, PhD, FACD, de The University of Sydney, and Montaser Shaheen, MD, from the University of Arizona Cancer center. The KOLs will discuss the clinical relevance of the updated KEYNOTE-695 data presented in a poster at the SITC 2021 annual meeting. Specifically, the KEYNOTE-695 clinical trial recruited patients with metastatic melanoma refractory to blockade. immune checkpoints, non-responders as defined by the recommendations of the Society of Immunotherapy of Cancer (SITC).1
Adil daud, MD, professor of medicine at University of California, San Francisco, Director of Clinical Melanoma Research, said: “TAVO works by optimizing cellular uptake of DNA-based IL-12 in the tumor microenvironment, leading to local and sustained production of IL-12 in the tumor, where it matters. TAVO recruits and primers cancer-fighting immune cells in the tumor, resulting in systemic immune responses without systemic toxicity, and we look forward to updated data at SITC 2021 in this highly refractory patient population. “
To register for the event, please click here.
1Kluger HM, Tawbi HA, Ascierto ML et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance working group. Journal for ImmunoTherapy of Cancer 2020; 8: e000398. doi: 10.1136 / jitc-2019-000398
About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the “Company”, “OncoSec”, “we” or “our”) is a biotechnology company focused on the development of intratumoral cytokine-based immunotherapies. OncoSec’s main investigational product in immunotherapy – TAVO ™ (tavokinogen telseplasmid) – is a DNA plasmid encoding interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions, which is administered by intratumoral injection and electroporation. The technology is designed to produce controlled and localized expression of IL-12 in the tumor microenvironment, enabling the activation of a tumor-specific systemic immune response to target and attack tumors throughout the body. OncoSec has built a clinical pipeline using TAVO ™ in combination with checkpoint inhibitors as a potential treatment for multiple cancer indications, with the goal of addressing a large unmet medical need in oncology: disease resistance to treatment with checkpoint inhibitors. The results of clinical studies In clinical studies, TAVO ™, either as monotherapy or in combination with checkpoint inhibitors, demonstrated the induction of a local tumor immune response and a systemic antitumor effect, as well as a acceptable safety profile, justifying further development. In addition to TAVO ™, OncoSec identifies and develops novel DNA-encoded therapeutic candidates and visceral lesion applicator, to target deeper visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.
TAVO ™ is a trademark of OncoSec Medical Incorporated.
Risk factors and forward-looking statements
This press release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements which involve a number of risks and uncertainties which could cause actual results to differ materially from those. anticipated in the declarations. Forward-looking statements provide the Company’s current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the control of the Company) and assumptions. For these statements, we claim the safe harbor protection for the forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify the forward-looking statements by the fact that they do not relate strictly to historical facts or current. These statements may include words such as “anticipate”, “believe”, “might”, “estimate”, “expect”, “intend”, “may”, “” “and” would. And similar expressions (including the negative of these terms). Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Company intends that these forward-looking statements speak only as of the time they are issued on or as otherwise specified and does not undertake to update or revise these statements as more information becomes available, except as required by federal securities laws and the rules and regulations of the Securities Exchange Commission (“SEC”). In particular, you should be aware that success and the timing of our clinical trials, including the safety and efficacy of our product candidates, the accumulation of patients, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or The initiation or completion of clinical trials and the ease of use of the data generated by our trials may differ and not meet our estimated timeframes. Please refer to the risk factors and other caveats provided in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020 and subsequent periodic and current reports filed with the SEC (each of which can be viewed on the SEC website www.sec.gov), as well as other factors described from time to time in the Company’s filings with the SEC.
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncosec-medical-hosting-sitc-key-opinion-leader-webinar-on-updated-data-from-the-keynote-695-study-301413873.html
SOURCE OncoSec Medical Incorporated